Literature DB >> 6847722

IgG and IgM rheumatoid factors in rheumatoid arthritis. Quantitative response to penicillamine therapy and relationship to disease activity.

R Wernick, P Merryman, I Jaffe, M Ziff.   

Abstract

Penicillamine treatment of patients with rheumatoid arthritis (RA) leads to falling titers of agglutinating IgM rheumatoid factor (RF), but its effect on IgG RF has not been described. Using specific solid phase radioimmunoassays, we have determined serial levels of IgM RF and IgG RF in 18 patients receiving penicillamine for 1 year, and correlated the results with the change in RA activity. Mean IgM RF levels fell to 76 +/- 10% (mean +/- SEM) after 3 months, and 30 +/- 5% of the pretreatment value after 1 year of penicillamine treatment. This decline was greater than that for total IgM (P less than 0.0001), indicating a selective reduction of RF. Patients receiving maintenance doses of 750 mg/day manifested more rapid and greater decreases than did those given 250 mg/day. In contrast, serial mean IgG RF levels did not change significantly, and actually increased in 6 of 18 cases. At onset, there was a significant correlation with erythrocyte sedimentation rate for both IgM RF (r = 0.535, P = 0.05) and IgG RF levels (r = 0.570, P = 0.02). But changes in RF concentration demonstrated no correlation with changes in either erythrocyte sedimentation rate or joint score over the 1-year period, suggesting that circulating IgM RF or IgG RF levels may be unrelated to the degree of RA activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847722     DOI: 10.1002/art.1780260503

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

Review 1.  Best practice in primary care pathology: review 6.

Authors:  W S A Smellie; J Forth; J J Coleman; W Irvine; P C Dore; G Handley; D G Williams; P J Galloway; K G Kerr; R Herriot; G P Spickett; T M Reynolds
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

2.  D-penicillamine and rheumatoid factor.

Authors:  D R Stanworth
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

3.  Evidence for oligoclonal B cell expansion in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D A Fox; B R Smith
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

Review 4.  Immunotoxic side-effects of drug therapy.

Authors:  J A Mitchell; E M Gillam; L A Stanley; E Sim
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

5.  Measurement of plasma concentrations of polymorphonuclear elastase-alpha 1 proteinase inhibitor (elastase-alpha 1 antitrypsin) in patients with rheumatoid arthritis: interference by rheumatoid factor.

Authors:  R E Banks; S W Evans; K F Taylor; H A Bird; J T Whicher
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

6.  Inhibition of the covalent binding reaction of complement component C4 by penicillamine, an anti-rheumatic agent.

Authors:  E Sim; A W Dodds; A Goldin
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

7.  Clinical value of ELISA assays for IgM and IgG rheumatoid factors.

Authors:  R Stone; J S Coppock; P T Dawes; P A Bacon; D L Scott
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

Review 8.  New perspectives of secondary and tertiary therapy for rheumatoid arthritis.

Authors:  R F Willkens
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

9.  Proteoglycan biosynthesis by rabbit articular chondrocytes treated with D-penicillamine.

Authors:  P Legendre; M Bouakka; M Langris; J P Pujol; R Beliard; G Loyau; J Bocquet
Journal:  Agents Actions       Date:  1988-08

10.  Lymphoid irradiation in intractable rheumatoid arthritis: effects on the production of immunoglobulins and rheumatoid factors.

Authors:  J G Hanly; J Hassan; M Moriarty; A Whelan; C Feighery; B Bresnihan
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.